高斯贝尔(002848) - 2020 Q3 - 季度财报

Financial Performance - Operating revenue for the reporting period was ¥109,657,780.64, down 19.88% year-on-year, and down 36.97% for the year-to-date[9] - Net profit attributable to shareholders of the listed company was -¥106,400,395.88, a decrease of 3,709.46% year-on-year[9] - Basic earnings per share were -¥0.6366, reflecting a decline of 3,717.05% compared to the same period last year[9] - The net cash flow from operating activities was -¥3,426,626.73, a decrease of 2,195.43% year-on-year[9] - Operating revenue fell by 36.97% to ¥260,224,270.36, primarily impacted by the pandemic and Sino-Indian relations[18] - The net profit for Q3 2020 was a loss of CNY 106,629,996.98, compared to a profit of CNY 2,947,818.32 in Q3 2019, indicating a significant decline in profitability[44] - The company's total operating revenue for the current period is CNY 56,163,354.99, a decrease of 48.3% compared to CNY 108,783,800.82 in the previous period[47] - The net profit for the current period is a loss of CNY 90,486,474.16, compared to a profit of CNY 3,450,809.22 in the previous period[48] - The total comprehensive income for the current period is -90,486,474.16, compared to 3,450,809.22 in the previous period[49] - The total profit (loss) for the period was -¥124,244,220.47, compared to -¥34,458,488.82 in the previous year, indicating a worsening financial position[54] Assets and Liabilities - Total assets at the end of the reporting period were ¥972,200,484.64, a decrease of 8.89% compared to the end of the previous year[9] - The company's total assets decreased to CNY 913,542,841.62 from CNY 996,875,819.82, reflecting a reduction of about 8.3% year-over-year[40] - The total liabilities increased slightly to ¥398.24 million from ¥390.16 million, an increase of about 2.8%[36] - The total liabilities decreased to CNY 333,542,523.55 from CNY 342,917,525.71, a reduction of approximately 2.5%[40] - The company's equity attributable to shareholders of the parent company decreased to CNY 574,090,497.72 from CNY 676,835,325.60, a decline of about 15.2%[39] - The total current liabilities were 371,698,386.40 yuan, consistent with the previous period[68] Cash Flow - Cash and cash equivalents increased by 48.69% to ¥49,490,621.11 due to loans received from Bincheng Investment Company[17] - The net cash flow from operating activities was a negative ¥37,046,451.29, a decline of 363.66% due to reduced business volume and slower collections[18] - Cash inflow from financing activities increased to 76,840,000.00 yuan, compared to 60,925,784.00 yuan in the previous period, reflecting a 26.1% increase[64] - The net increase in cash and cash equivalents for the current period was 14,969,272.89 yuan, reversing a decrease of 14,988,320.70 yuan in the previous period[64] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 20,396[13] - The largest shareholder, Liu Tanai, holds 27.93% of the shares, amounting to 46,690,300 shares, with 40,250,000 shares pledged[13] - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[14] Research and Development - Research and development expenses for Q3 2020 were CNY 11,394,678.24, compared to CNY 10,090,743.08 in Q3 2019, indicating an increase of approximately 12.9%[43] - The company's research and development expenses were ¥18,408,147.18, slightly up from ¥17,442,944.81 year-over-year, showing continued investment in innovation[54] Other Information - The company completed the registration of changes to its business scope, adding "R&D of Class II medical devices" and other new areas[19] - A proposal to establish a wholly-owned subsidiary was approved by the board on September 30, 2020, with registration completed in October[20] - The company has not engaged in any securities or derivative investments during the reporting period[23][24] - There were no violations regarding external guarantees or non-operating fund occupation by major shareholders during the reporting period[28][29] - The company has not reported any significant changes in its operating performance or major contracts that would affect the financial results[25][30] - The third-quarter report was not audited, which may impact the reliability of the financial data presented[75]